An abluminal biodegradable polymer sirolimus-eluting stent versus a durable polymer everolimus-eluting stent in patients undergoing coronary revascularization:3-year clinical outcomes of a randomized non-inferiority trial

Autor: Xiao-Ping Zhang, Lu Shoutao, Haijun Zhang, Wei Deng, Duan Cuihai, Fei Yang, Junbo Ge, Hou Wenbo, Chao Zhou, Yin Yuxia, Shenguo Wang, Cui Xiaoshan, Liu Guang, Song Caixia, Zhang Junwei
Jazyk: angličtina
Rok vydání: 2019
Předmět:
Male
Polymers
medicine.medical_treatment
Myocardial Infarction
lcsh:Medicine
Aftercare
030204 cardiovascular system & hematology
Ischaemia
law.invention
0302 clinical medicine
Randomized controlled trial
Polymers/chemistry
law
Absorbable Implants
Clinical endpoint
Medicine
030212 general & internal medicine
Myocardial infarction
Everolimus/administration & dosage
lcsh:Science
Percutaneous Coronary Intervention/adverse effects
Multidisciplinary
Absolute risk reduction
Drug-Eluting Stents
Middle Aged
Treatment Outcome
Female
Interventional cardiology
medicine.medical_specialty
Delayed-Action Preparations/administration & dosage
Sirolimus/administration & dosage
Article
03 medical and health sciences
Percutaneous Coronary Intervention
Multicenter trial
Myocardial Infarction/epidemiology
Humans
Everolimus
Aged
Sirolimus
business.industry
Absorbable Implants/adverse effects
lcsh:R
Drug-Eluting Stents/adverse effects
Coronary Stenosis
Stent
Thrombosis
medicine.disease
equipment and supplies
Surgery
Stenosis
Delayed-Action Preparations
lcsh:Q
Thrombosis/epidemiology
Coronary Stenosis/complications
business
Zdroj: Zhang, H, Zhang, X, Yin, Y, Zhou, C, Deng, W, Zhang, J, Hou, W, Lu, S, Song, C, Cui, X, Wang, S, Yang, F, Liu, G, Duan, C & Ge, J 2019, ' An abluminal biodegradable polymer sirolimus-eluting stent versus a durable polymer everolimus-eluting stent in patients undergoing coronary revascularization : 3-year clinical outcomes of a randomized non-inferiority trial ', Scientific Reports, vol. 9, no. 1, 18549 . https://doi.org/10.1038/s41598-019-54964-8
Scientific Reports
Scientific Reports, Vol 9, Iss 1, Pp 1-10 (2019)
DOI: 10.1038/s41598-019-54964-8
Popis: The Cordimax stent has proved non-inferior to the Cypher Select durable polymer sirolimus-eluting stent for the primary endpoint of angiographic in-stent late luminal loss and in-stent mean diameter stenosis at 9 months. The trial was designed to compare the efficacy and safety of the Cordimax stent with the Xience V stent in patients undergoing coronary revascularization. This randomized, multicenter trial enrolled 3697 patients treated with Cordimax stent (2460 patients) and Xience V stent (1237 patients). The primary efficacy endpoint was a target-lesion failure (TLF) at 1 year and the primary safety endpoint was a composite of death or myocardial infarction (MI) at 3 years. 3399 patients (91.9%) completed 3-year follow-up. At 1 year, the primary efficacy endpoint occurred in 86 (3.5%) patients in the Cordimax group versus 40 (3.2%) patients in the Xience V group (0.3% absolute risk difference, 95% CI −1.0–1.5%, Pnon-inferiority Pnon-inferiority P = 0.03). There were no differences between Cordimax and Xience V in terms of Cardiac death (0.3% versus 0.4%, P = 0.70), myocardial infarction (1.2% versus 0.9%, P = 0.37), and the stent thrombosis (0.4% versus 0.6%, P = 0.61). In conclusion, safety and efficacy outcomes of Cordimax stent were non-inferior to the Xience V stent 3 years after stent implantation.
Databáze: OpenAIRE
Externí odkaz: